TransCode Therapeutics (NASDAQ:RNAZ) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZFree Report) in a research note released on Thursday, Benzinga reports. The firm currently has a $3.00 price objective on the stock.

TransCode Therapeutics Stock Performance

RNAZ stock opened at $1.15 on Thursday. TransCode Therapeutics has a 1-year low of $0.42 and a 1-year high of $309.60. The business has a 50 day simple moving average of $0.70 and a two-hundred day simple moving average of $3.81.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sabby Management LLC grew its position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZFree Report) by 32.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 250,309 shares of the company’s stock after acquiring an additional 61,872 shares during the quarter. Sabby Management LLC owned about 12.33% of TransCode Therapeutics worth $126,000 at the end of the most recent reporting period.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.

Recommended Stories

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.